Tenaya Therapeutics (TNYA)

Company Profile

Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.

Company profile

Ticker

TNYA

Exchange

Incorporated

Location

Fiscal year end

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...

SEC CIK

0001858848

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

IRS number

813789973

TNYA stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$24.50

Low target

$21.00

High target

$28.00

Latest filings (excl ownership)

View all

8-K

Tenaya Therapeutics Announces Pricing of Public Offering

17 Nov 22

424B5

Prospectus supplement for primary offering

17 Nov 22

424B5

Prospectus supplement for primary offering

10 Nov 22

Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

10 Nov 22

EFFECT

Notice of effectiveness

18 Aug 22

424B5

Prospectus supplement for primary offering

17 Aug 22

CORRESP

Correspondence with SEC

Entry into a Material Definitive Agreement

10 Aug 22

Latest ownership filings

View all

Change in insider ownership

Karah Herdman Parschauer

9 Sep 22

Jeffrey T. Walsh

13 Jun 22

Catherine Stehman-Breen

13 Jun 22

Deepak Srivastava

13 Jun 22

Financial summary

Financial statements Chart TNYA financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	34.89 mm	34.89 mm	34.89 mm	34.89 mm		34.89 mm
Cash burn (monthly)	(no burn)	6.89 mm	10.43 mm	9.77 mm		2.40 mm
Cash used (since last report)	n/a	14.52 mm	21.97 mm	20.57 mm		5.05 mm
Cash remaining	n/a	20.37 mm	12.92 mm	14.32 mm		29.85 mm
Runway (months of cash)	n/a	3.0	1.2	1.5		12.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

TNYA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	66	50	+32.0%
Opened positions	21	6	+250.0%
Closed positions	5	6	-16.7%
Increased positions	20	11	+81.8%
Reduced positions	9	21	-57.1%

13F shares	Current	Prev Q	Change
Total value	275.68 mm	381.62 mm	-27.8%
Total shares	43.02 mm	45.55 mm	-5.5%
Total puts	24.10 k	0.00	NEW
Total calls	0.00	0.00
Total put/call ratio	Infinity	–	–

Largest owners	Shares	Value	Change
Column Group Iii	9.40 mm	$178.14 mm	0.0%
Column	9.40 mm	$27.26 mm	0.0%
Casdin Capital	3.59 mm	$10.40 mm	0.0%
FMR	3.13 mm	$9.06 mm	-43.5%
RTW Investments	2.46 mm	$7.13 mm	0.0%
BLK Blackrock	2.44 mm	$7.08 mm	-0.9%
T. Rowe Price	2.11 mm	$6.13 mm	-37.2%
Regents Of The University Of California	1.63 mm	$4.72 mm	NEW
Ra Capital Management	1.60 mm	$4.65 mm	-54.9%
T. Rowe Price Investment Management	1.56 mm	$4.54 mm	NEW

Largest transactions	Shares	Bought/sold	Change
FMR	3.13 mm	-2.40 mm	-43.5%
Ra Capital Management	1.60 mm	-1.95 mm	-54.9%
Regents Of The University Of California	1.63 mm	+1.63 mm	NEW
T. Rowe Price Investment Management	1.56 mm	+1.56 mm	NEW
T. Rowe Price	2.11 mm	-1.25 mm	-37.2%
Deep Track Capital	0.00	-483.84 k	EXIT
STT State Street	0.00	-390.42 k	EXIT
Commodore Capital	0.00	-357.70 k	EXIT
Citadel Advisors	217.34 k	+168.38 k	+343.9%
Renaissance Technologies	166.20 k	+166.20 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

TNYA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
21 Nov 22	David V Goeddel	Common Stock	Buy	Acquire P	Yes	No	2.6	9,615,384	25.00 mm	9,615,384
21 Nov 22	Column Group Iii GP	Common Stock	Buy	Acquire P	Yes	No	2.6	9,615,384	25.00 mm	9,615,384
17 Nov 22	Casdin Eli	Common Stock	Buy	Acquire P	Yes	No	2.6	2,492,042	6.48 mm	6,078,860
17 Nov 22	Casdin Eli	Warrant Common Stock	Buy	Acquire P	Yes	No	2.599	1,354,111	3.52 mm	1,354,111
8 Sep 22	Karah Herdman Parschauer	Stock Option Common Stock	Grant	Acquire A	No	No	4.82	20,000	96.40 k	20,000
10 Jun 22	Chen Jin-long	Stock Option Common Stock	Grant	Acquire A	No	No	5.26	39,727	208.96 k	39,727